AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
FACTORS THAT INFLUENCE THE ANTIEMETIC ACTIVITY OF METOCLOPRAMIDE TO CISPLATIN-BASED CHEMOTHERAPY
Authors: TSAVARIS N MYLONAKIS N BACOYIANNIS C KOSMAS C KALERGIS G IAKOVIDIS V TZANINIS D KOSMIDIS P
Citation: N. Tsavaris et al., FACTORS THAT INFLUENCE THE ANTIEMETIC ACTIVITY OF METOCLOPRAMIDE TO CISPLATIN-BASED CHEMOTHERAPY, Oncology Reports, 5(5), 1998, pp. 1147-1155
A RANDOMIZED COMPARATIVE-STUDY OF ANTIEMETIC PROPHYLAXIS WITH ONDANSENTRON IN A SINGLE 32-MG LOADING DOSE VERSUS 8 MG EVERY 6 H IN PATIENTSUNDERGOING CISPLATIN-BASED CHEMOTHERAPY
Authors: TSAVARIS N FOUNTZILAS G MYLONAKIS N ATHANASSIADIS A KOSMAS C KARAKOUSIS C BACOYIANNIS C KOSMIDIS P
Citation: N. Tsavaris et al., A RANDOMIZED COMPARATIVE-STUDY OF ANTIEMETIC PROPHYLAXIS WITH ONDANSENTRON IN A SINGLE 32-MG LOADING DOSE VERSUS 8 MG EVERY 6 H IN PATIENTSUNDERGOING CISPLATIN-BASED CHEMOTHERAPY, Oncology, 55(6), 1998, pp. 513-516
CONTRIBUTION OF CHEMOTHERAPY (CMT) TO THE SURVIVAL(S) OF PATIENTS(P) WITH ADVANCED GASTRIC-CANCER (AGC) - A RETROSPECTIVE COMPARATIVE-STUDYOF PATIENTS WHO RECEIVED AND THOSE WHO REFUSED TREATMENT (TX)
Authors: TSAVARIS N KOSMIDIS P KOSMAS C KATSIKAS M BACOYIANNIS C MYLONAKIS N PAPALAMBROS E KOUFOS C BASTOUNIS E SECHAS M
Citation: N. Tsavaris et al., CONTRIBUTION OF CHEMOTHERAPY (CMT) TO THE SURVIVAL(S) OF PATIENTS(P) WITH ADVANCED GASTRIC-CANCER (AGC) - A RETROSPECTIVE COMPARATIVE-STUDYOF PATIENTS WHO RECEIVED AND THOSE WHO REFUSED TREATMENT (TX), European journal of cancer, 33, 1997, pp. 1276-1276
PACLITAXEL AND CARBOPLATIN IN INOPERABLE NON-SMALL-CELL LUNG-CANCER -A PHASE-II STUDY
Authors: KOSMIDIS PA MYLONAKIS N FOUNTZILAS G SAMANTAS E ATHANASIADIS A ANDREOPOULOU E PAVLIDIS N SKARLOS D
Citation: Pa. Kosmidis et al., PACLITAXEL AND CARBOPLATIN IN INOPERABLE NON-SMALL-CELL LUNG-CANCER -A PHASE-II STUDY, Annals of oncology, 8(7), 1997, pp. 697-699
INTENSIFIED CARBOPLATIN REGIMEN WITH GM-CSF SUPPORT IN NONSMALL CELL LUNG-CANCER (NSCLC) - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY (HECOG)
Authors: NICOLAIDES C KLOUVAS G FOUNTZILAS G ATHANASSIADIS A SKARLOS D SAMANTAS E KOSMIDIS P MYLONAKIS N PAVLIDIS N
Citation: C. Nicolaides et al., INTENSIFIED CARBOPLATIN REGIMEN WITH GM-CSF SUPPORT IN NONSMALL CELL LUNG-CANCER (NSCLC) - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY (HECOG), Journal of experimental & clinical cancer research, 16(1), 1997, pp. 91-94
COMBINATION CHEMOTHERAPY WITH CISPLATIN AND OR DOXORUBICIN IN MALIGNANT MESOTHELIOMA - A PROSPECTIVE-STUDY/
Authors: TSAVARIS N PRIMIKIRIOS N MYLONAKIS N VAROUCHAKIS G DOSIOS T PAVLIDIS N SKARLOS D TASOPOULOS T DRITSAS J KOSMIDIS P
Citation: N. Tsavaris et al., COMBINATION CHEMOTHERAPY WITH CISPLATIN AND OR DOXORUBICIN IN MALIGNANT MESOTHELIOMA - A PROSPECTIVE-STUDY/, Anticancer research, 17(5B), 1997, pp. 3799-3802
PACLITAXEL (175 MG M(2)) PLUS CARBOPLATIN VERSUS PACLITAXEL (225 MG/M(2)) PLUS CARBOPLATIN IN NONSMALL CELL LUNG-CANCER - A RANDOMIZED STUDY/
Authors: KOSMIDIS P MYLONAKIS N FOUNTZILAS G SAMANTAS E ATHANASSIADIS A PAVLIDIS N SKARLOS D
Citation: P. Kosmidis et al., PACLITAXEL (175 MG M(2)) PLUS CARBOPLATIN VERSUS PACLITAXEL (225 MG/M(2)) PLUS CARBOPLATIN IN NONSMALL CELL LUNG-CANCER - A RANDOMIZED STUDY/, Seminars in oncology, 24(4), 1997, pp. 30-33
CARBOPLATIN ALONE COMPARED WITH ITS COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN UNTREATED ADVANCED EPITHELIAL OVARIAN-CANCER - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY
Authors: SKARLOS DV ARAVANTINOS G KOSMIDIS P PAVLIDIS N GENNATAS K BEER M MYLONAKIS N MAKRANTONAKIS P KLOUVAS G KARPATHIOS S LINARDOU H KONSTANTARAS C FOUNTZILAS G
Citation: Dv. Skarlos et al., CARBOPLATIN ALONE COMPARED WITH ITS COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN UNTREATED ADVANCED EPITHELIAL OVARIAN-CANCER - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY, European journal of cancer, 32A(3), 1996, pp. 421-428
A PROSPECTIVE RANDOMIZED PHASE-III STUDY IN NON-SMALL-CELL LUNG-CANCER COMPARING CISPLATIN, IFOSFAMIDE, VINBLASTINE (VIP) VERSUS CISPLATIN,IFOSFAMIDE AND ETOPOSIDE (VIP-16)
Authors: KOSMIDIS P MYLONAKIS N FOUNTZILAS G PAVLIDIS N SAMANTAS E KARABELIS A KATTIS K SKARLOS D
Citation: P. Kosmidis et al., A PROSPECTIVE RANDOMIZED PHASE-III STUDY IN NON-SMALL-CELL LUNG-CANCER COMPARING CISPLATIN, IFOSFAMIDE, VINBLASTINE (VIP) VERSUS CISPLATIN,IFOSFAMIDE AND ETOPOSIDE (VIP-16), Annals of oncology, 7(5), 1996, pp. 517-520
5-FLUOROURACIL, EPIRUBICIN, AND MITOMYCIN-C VERSUS 5-FLUOROURACIL, EPIRUBICIN, MITOMYCIN-C, AND LEUCOVORIN IN ADVANCED GASTRIC-CARCINOMA - A RANDOMIZED TRIAL
Authors: TSAVARIS NB TENTAS K KOSMIDIS P MYLONAKIS N SAKELAROPOULOS N KOSMAS C LISAIOS B SOUMILAS A MANDREKOIS D TSETIS A KLONARIS C
Citation: Nb. Tsavaris et al., 5-FLUOROURACIL, EPIRUBICIN, AND MITOMYCIN-C VERSUS 5-FLUOROURACIL, EPIRUBICIN, MITOMYCIN-C, AND LEUCOVORIN IN ADVANCED GASTRIC-CARCINOMA - A RANDOMIZED TRIAL, American journal of clinical oncology, 19(5), 1996, pp. 517-521
PACLITAXEL AND CARBOPLATIN IN INOPERABLE NONSMALL CELL LUNG-CANCER
Authors: KOSMIDIS P MYLONAKIS N FOUNTZILAS G SAMANTAS E ATHANASIADIS A SKARLOS D
Citation: P. Kosmidis et al., PACLITAXEL AND CARBOPLATIN IN INOPERABLE NONSMALL CELL LUNG-CANCER, Seminars in oncology, 23(6), 1996, pp. 68-70
PACLITAXEL AND CARBOPLATIN IN NONOPERABLE NONSMALL CELL LUNG-CANCER
Authors: KOSMIDIS P MYLONAKIS N FOUNTZILAS G SAMANTAS E ATHANASIADIS A SKARLOS D
Citation: P. Kosmidis et al., PACLITAXEL AND CARBOPLATIN IN NONOPERABLE NONSMALL CELL LUNG-CANCER, Seminars in oncology, 23(6), 1996, pp. 16-18
CYCLOPHOSPHAMIDE, MITOXANTRONE, FLUOROURACIL VERSUS CONVENTIONAL CMF AS ADJUVANT TREATMENT IN NODE-POSITIVE BREAST-CANCER PATIENTS - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY
Authors: FOUNTZILAS G KATSOHIS K TOUSSIS D KOSMIDIS P SEMOGLOU C FAHANTIDIS E TSAVARIS N MAKRANTONAKIS P ZAMBOGLOU N HAINOGLOU D PAVLIDIS N POLICHRONIS A GENNATAS K SKARLOS D VASSILAROS S GIANNAKAKIS T KLOUVAS G KONSTANTARAS C KOLOTAS C TSILIAKOS S MYLONAKIS N
Citation: G. Fountzilas et al., CYCLOPHOSPHAMIDE, MITOXANTRONE, FLUOROURACIL VERSUS CONVENTIONAL CMF AS ADJUVANT TREATMENT IN NODE-POSITIVE BREAST-CANCER PATIENTS - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY, Oncology, 53(2), 1996, pp. 137-146
A RANDOMIZED TRIAL COMPARING ADJUVANT FLUOROURACIL, EPIRUBICIN, AND MITOMYCIN WITH NO TREATMENT IN OPERABLE GASTRIC-CANCER
Authors: TSAVARIS N TENTAS K KOSMIDIS P MYLONAKIS N SAKELAROPOULOS N KOSMAS C LISAIOS B SOUMILAS A MANDREKAS D TSETIS A KLONARIS C
Citation: N. Tsavaris et al., A RANDOMIZED TRIAL COMPARING ADJUVANT FLUOROURACIL, EPIRUBICIN, AND MITOMYCIN WITH NO TREATMENT IN OPERABLE GASTRIC-CANCER, Chemotherapy, 42(3), 1996, pp. 220-226
USE OF NAPROXEN IN AMELIORATING INDUCED PARANEOPLASTIC FEVER
Authors: TSAVARIS N MYLONAKIS N BACOYIANNIS C KARVOUNIS N KORDOSSIS T DALIANI D KARABELIS A KOSMIDIS P
Citation: N. Tsavaris et al., USE OF NAPROXEN IN AMELIORATING INDUCED PARANEOPLASTIC FEVER, Clinical drug investigation, 10(1), 1995, pp. 8-11
A COMPARATIVE-STUDY WITH 2 ADMINISTRATION SCHEDULES OF LEUCOVORIN AND5-FLUOROURACIL IN ADVANCED COLORECTAL-CANCER
Authors: TSAVARIS N FOUTZILAS G MARKANTONAKIS P MYLONAKIS N BACOYANNIS C ZISIADIS A BASDANIS G KARVOUNIS N SOBOLOS K KOSMIDIS P
Citation: N. Tsavaris et al., A COMPARATIVE-STUDY WITH 2 ADMINISTRATION SCHEDULES OF LEUCOVORIN AND5-FLUOROURACIL IN ADVANCED COLORECTAL-CANCER, Journal of chemotherapy, 7(1), 1995, pp. 71-77
COMBINED EPIRUBICIN, EPIRUBICIN, 5-FLUOROURACIL AND FOLINIC ACID WITHALLOPURINOL PROTECTION FOR 2ND-LINE TREATMENT OF ADVANCED GASTRIC-CANCER - A PILOT-STUDY
Authors: TSAVARIS N MYLONAKIS N BACOYIANNIS C PAPASTRATIS G KATSIKAS M PAPADIMITRAKOPOULOU V MACHERAS A STAMELOU A KOSMIDIS P
Citation: N. Tsavaris et al., COMBINED EPIRUBICIN, EPIRUBICIN, 5-FLUOROURACIL AND FOLINIC ACID WITHALLOPURINOL PROTECTION FOR 2ND-LINE TREATMENT OF ADVANCED GASTRIC-CANCER - A PILOT-STUDY, Onkologie, 18(4), 1995, pp. 346-350
ONDANSETRON VERSUS METOCLOPRAMIDE AS ANTIEMETIC TREATMENT DURING CISPLATIN-BASED CHEMOTHERAPY - A PROSPECTIVE-STUDY WITH SPECIAL REGARD TO ELECTROLYTE IMBALANCE
Authors: TSAVARIS N CHARALAMBIDIS G GANAS N PAGOU M KARABELLIS A MYLONAKIS N BENOU N TSIKALAKIS D KOSMIDIS P
Citation: N. Tsavaris et al., ONDANSETRON VERSUS METOCLOPRAMIDE AS ANTIEMETIC TREATMENT DURING CISPLATIN-BASED CHEMOTHERAPY - A PROSPECTIVE-STUDY WITH SPECIAL REGARD TO ELECTROLYTE IMBALANCE, Acta oncologica, 34(2), 1995, pp. 243-246
EFFICACY OF ONDANSETRON TREATMENT WITH DIFFERENT TIMING SCHEDULES - ARANDOMIZED DOUBLE-BLIND-STUDY
Authors: TSAVARIS N MYLONAKIS N BACOYIANNIS C KARVOUNIS N CHARALAMBIDIS G PAGOU M LIONI A DALIANI D KOSMIDIS P
Citation: N. Tsavaris et al., EFFICACY OF ONDANSETRON TREATMENT WITH DIFFERENT TIMING SCHEDULES - ARANDOMIZED DOUBLE-BLIND-STUDY, Oncology, 52(4), 1995, pp. 315-318
RANDOMIZED COMPARISON OF ETOPOSIDE-CISPLATIN VS ETOPOSIDE-CARBOPLATINAND IRRADIATION IN SMALL-CELL LUNG-CANCER - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY
Authors: SKARLOS DV SAMANTAS E KOSMIDIS P FOUNTZILAS G ANGELIDOU M PALAMIDAS P MYLONAKIS N PROVATA A PAPADAKIS E KLOUVAS G THEOCHARIS D PANOUSAKI E BOLETI E SPHAKIANOUDIS G PAVLIDIS N
Citation: Dv. Skarlos et al., RANDOMIZED COMPARISON OF ETOPOSIDE-CISPLATIN VS ETOPOSIDE-CARBOPLATINAND IRRADIATION IN SMALL-CELL LUNG-CANCER - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY, Annals of oncology, 5(7), 1994, pp. 601-607
A COMPARATIVE-STUDY OF CISPLATIN AND VINBLASTINE VERSUS IFOSFAMIDE, CISPLATIN AND VINBLASTINE IN NON-OPERABLE NON-SMALL-CELL LUNG-CANCER
Authors: KOSMIDIS P MYLONAKIS N SKARLOS DV SAMANTAS E BEER M THEOCHARIS D ZACHARIADIS E GIOTI A PAPADAKIS E POULAKIS N PARASTATIDIS S FOUNTZILAS G
Citation: P. Kosmidis et al., A COMPARATIVE-STUDY OF CISPLATIN AND VINBLASTINE VERSUS IFOSFAMIDE, CISPLATIN AND VINBLASTINE IN NON-OPERABLE NON-SMALL-CELL LUNG-CANCER, Annals of oncology, 5(2), 1994, pp. 159-162
COMPARISON OF ONDANSENTRON VERSUS ONDANSENTRON PLUS METHYLPREDNISOLONE AS ANTIEMETIC PROPHYLAXIS DURING CISPLATIN-CONTAINING CHEMOTHERAPY
Authors: TSAVARIS N MYLONAKIS N BACOYIANNIS C KATSIKAS M LIONI A KOSMIDIS P
Citation: N. Tsavaris et al., COMPARISON OF ONDANSENTRON VERSUS ONDANSENTRON PLUS METHYLPREDNISOLONE AS ANTIEMETIC PROPHYLAXIS DURING CISPLATIN-CONTAINING CHEMOTHERAPY, Journal of pain and symptom management, 9(4), 1994, pp. 254-258
AN ALTERNATIVE SCHEDULE BASED ON IFOSFAMIDE (IFM) IN COMBINATION WITHDOXORUBICIN (ADM), VINCRISTIN (VCR) AND ACTINOMYCIN-D (ACTD) IN ADVANCED SOFT-TISSUE SARCOMAS (STS) OF ADULTS - A PILOT-STUDY
Authors: TSAVARIS N BACOYIANNIS C MYLONAKIS N KARVOUNIS N ZINELIS A TSOUTSOS E KOSMIDIS P
Citation: N. Tsavaris et al., AN ALTERNATIVE SCHEDULE BASED ON IFOSFAMIDE (IFM) IN COMBINATION WITHDOXORUBICIN (ADM), VINCRISTIN (VCR) AND ACTINOMYCIN-D (ACTD) IN ADVANCED SOFT-TISSUE SARCOMAS (STS) OF ADULTS - A PILOT-STUDY, Journal of experimental & clinical cancer research, 13(4), 1994, pp. 405-408
COMPARISON OF ONDANSENTRON (GR 3X032F) VERSUS ONDANSENTRON PLUS ALPRAZOLAM AS ANTIEMETIC PROPHYLAXIS DURING CISPLATIN-CONTAINING CHEMOTHERAPY
Authors: TSAVARIS N CHARALAMBIDIS G PAGOU M KARABELIS A MYLONAKIS N BACOYIANNIS C KOSMIDIS P
Citation: N. Tsavaris et al., COMPARISON OF ONDANSENTRON (GR 3X032F) VERSUS ONDANSENTRON PLUS ALPRAZOLAM AS ANTIEMETIC PROPHYLAXIS DURING CISPLATIN-CONTAINING CHEMOTHERAPY, American journal of clinical oncology, 17(6), 1994, pp. 516-521
COMBINATION CHEMOTHERAPY WITH CISPLATIN-VINBLASTINE IN MALIGNANT MESOTHELIOMA
Authors: TSAVARIS N MYLONAKIS N KARVOUNIS N BACOYIANNIS C BRIASOULIS E SKARLOS D PAVLIDIS N STAMATELOS G KOSMIDIS P
Citation: N. Tsavaris et al., COMBINATION CHEMOTHERAPY WITH CISPLATIN-VINBLASTINE IN MALIGNANT MESOTHELIOMA, Lung cancer, 11(3-4), 1994, pp. 299-303
Risultati: 1-25 | 26-26